Predictive Oncology Ebit Over Time
| POAI Stock | USD 0.81 0.03 3.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Predictive Oncology Performance and Predictive Oncology Correlation. Predictive |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.416 | Quarterly Revenue Growth (0.43) | Return On Assets (0.56) | Return On Equity (1.49) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebit Analysis
Compare Predictive Oncology and related stocks such as GlucoTrack, G Medical Innovations, and Sharps Technology Ebit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GCTK | 1.2 M | (2.3 M) | (2.8 M) | (3 M) | (3.6 M) | (5.9 M) | (5.7 M) | (10.6 M) | (6.5 M) | 3.5 M | (3.1 M) | (4 M) | (4.4 M) | (7.1 M) | (6.7 M) |
| STSS | (3.3 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.3 M) | (4.5 M) | (3.3 M) | (9.9 M) | (9.4 M) |
| MBOT | (6.6 M) | (34.2 M) | (22.1 M) | (32.8 M) | (32.2 M) | (37.7 M) | (9.9 M) | (3.2 M) | (7.2 M) | (7.2 M) | (9.1 M) | (11.4 M) | (13.3 M) | (10.7 M) | (11.3 M) |
| NXGL | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (969 K) | (1.9 M) | (1.9 M) | (2.3 M) | (2.3 M) | (3.4 M) | (3.2 M) | (3.3 M) |
| PDEX | (600 K) | (1.4 M) | (1.9 M) | (802 K) | (896 K) | 771 K | 2.9 M | 3.6 M | 5 M | 8.1 M | 7.3 M | 5.2 M | 5.8 M | 7.2 M | 7.5 M |
| LUCY | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (109.4 K) | (763.2 K) | (3.2 M) | (5.6 M) | (6.7 M) | (6.3 M) |
| ZJYL | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 2.5 M | 2.9 M | 2.7 M | 2.9 M | 2.6 M | 2.5 M |
| BNGO | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (22.9 M) | (22.4 M) | (25.9 M) | (38.6 M) | (77.8 M) | (130.4 M) | (227.3 M) | (215.9 M) |
| ISRG | (30.8 M) | 694.8 M | 878.1 M | 852.5 M | 544.8 M | 740 M | 945.2 M | 1.1 B | 1.2 B | 1.4 B | 767.3 M | 1.8 B | 1.2 B | 1.8 B | 1.9 B |
| STXS | (10.9 M) | (37.1 M) | (10.6 M) | (8.8 M) | (5.4 M) | (5.4 M) | (12.1 M) | (5.9 M) | (2.5 M) | (4.8 M) | (6.7 M) | (12.9 M) | (18.8 M) | (21.8 M) | (22.9 M) |
| NYXH | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (8.9 M) | (6.5 M) | (11.2 M) | (26.2 M) | (29.8 M) | (44.4 M) | (42.2 M) |
| DXR | 3.3 M | (12.2 M) | (2.7 M) | (8.2 M) | (4.5 M) | (7.9 M) | 1.5 M | (1.1 M) | (1.1 M) | (495.7 K) | (1.7 M) | 4.7 M | 5.3 M | (177.1 K) | (168.2 K) |
| MLSS | (2.3 M) | (1.1 M) | (691.3 K) | 172.1 K | (1.7 M) | (3.1 M) | (6.5 M) | (5.2 M) | (4.9 M) | (4 M) | (7.5 M) | (7.4 M) | (8.8 M) | (7.1 M) | (6.8 M) |
Predictive Oncology and related stocks such as GlucoTrack, G Medical Innovations, and Sharps Technology Ebit description
My Equities
My Current Equities and Potential Positions
| Predictive Oncology | POAI |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Minnesota; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.81
Check out Predictive Oncology Performance and Predictive Oncology Correlation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Predictive Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.